Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses

Journal of Neuroscience

Volumn 23, Issue 10, 2003, Pages 4315-4323

  Benedetti, Fabrizio ^a,c   Pollo, Antonella ^a   Lopiano, Leonardo ^a   Lanotte, Michele ^b   Vighetti, Sergio ^a   Rainero, Innocenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CTO HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Conditioning; Expectation; Hormones; Pain; Parkinson's disease; Placebo

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; KETOROLAC; PLACEBO; SEROTONIN AGONIST; SUMATRIPTAN; HUMAN GROWTH HORMONE;

ADULT; ANALGESIA; ARM; ARTICLE; COGNITION; CONDITIONING; EXPECTATION; FEMALE; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; MOTOR ACTIVITY; MOTOR PERFORMANCE; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; VERBAL BEHAVIOR; AGED; ATTITUDE TO HEALTH; BLOOD; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; INSTRUMENTAL CONDITIONING; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SECRETION; SUBTHALAMIC NUCLEUS; UNCONSCIOUSNESS;

AGED; ANALGESIA; ATTITUDE TO HEALTH; COGNITION; CONDITIONING, OPERANT; CONSCIOUSNESS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; KETOROLAC; MALE; MIDDLE AGED; MOTOR SKILLS; PAIN; PARKINSON DISEASE; PLACEBO EFFECT; SUBTHALAMIC NUCLEUS; SUMATRIPTAN; UNCONSCIOUSNESS;

EID: 0037704429     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-10-04315.2003     Document Type: Article

References (63)

1. Ader R (1985) Conditioned immunopharmacological effects in animals: implications for a conditioning model of pharmacotherapy. In: Placebo: theory, research, and mechanisms (White L, Tursky B, Schwartz GE, eds), pp 306-323. New York: Guilford.
2. Ader R (1997) The role of conditioning in pharmacotherapy. In: The placebo effect: an interdisciplinary exploration (Harrington A, ed), pp 138-165. Cambridge, MA: Cambridge UP.
3. Amanzio M, Benedetti F (1999) Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19:484-494.
4. Amanzio M, Pollo A, Maggi G, Benedetti F (2001) Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 90:205-215.
5. Benazzouz A, Hallett M (2000) Mechanism of action of deep brain stimulation. Neurology 55:S13-16.
6. Benedetti F (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64:535-543.
7. Benedetti F (2002) How the doctor's words affect the patient's brain. Eval Health Prof 25:369-386.
8. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G (1997) Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 70:431-436.
9. Benedetti F, Amanzio M, Baldi S, Casadio C, Maggi G (1999a) Inducing placebo respiratory depressant responses in humans via opioid receptors. Eur J Neurosci 11:625-631.
10. Benedetti F, Arduino C, Amanzio M (1999b) Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 19:3639-3648.
11. Benedetti F, Maggi G, Lopiano L, Lanotte M, Rainero I, Vighetti S, Pollo A (2003) Open versus hidden medical treatments: the patient's knowledge about a therapy affects the therapy outcome. Prevention and Treatment, in press.
12. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293:1164-1166.
13. Entwisle SJ, Fowler PA, Thomas M, Eckland DJA, Lettis S, York M, Freedman PS (1995) The effects of oral sumatriptan, 5HT1 receptor agonist, on circulating ACTH and cortisol concentrations in man. Br J Clin Pharmacol 39:389-395.
14. Fahn S, Elton RL, and the Members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Recent developments in Parkinson's disease (Fahn S, Marsden CD, Calne DB, eds), pp 153-163. London: MacMillan.
15. Flaten MA, Simonsen T, Olsen H (1999) Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosomat Med 61:250-255.
16. Franceschini R, Cataldi A, Garibaldi A, Cianciosi P, Scordamaglia A, Barreca T, Rolandi E (1994) The effects ofsumatriptan on pituitary secretion in man. Neuropharmacology 33:235-239.
17. Gleidman LH, Grantt WH, Teitelbaum HA (1957) Some implications of conditional reflex studies for placebo research. Am J Psychiat 113:1103-1107.
18. Grevert P, Albert LH, Goldstein A (1983) Partial antagonism of placebo analgesia by naloxone. Pain 16:129-143.
19. Hahn RA (1985) A sociocultural model of illness and healing. In: Placebo: theory, research, and mechanisms (White L, Tursky B, Schwartz GE, eds), pp 167-195. New York: Guilford.
20. Hahn RA (1997) The nocebo phenomenon: scope and foundations. In: The placebo effect: an interdisciplinary exploration (Harrington A, ed), pp 56-76. Cambridge, MA: Harvard UP.
21. Herrnstein RJ (1962) Placebo effect in the rat. Science 138:677-678.
22. Hutchinson WD, Allan RJ, Opitz H, Levy R, Dostrovsky JO, Lang AE, Lozano AM (1998) Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol 44:622-628.
23. Kennedy WP (1961) The nocebo reaction. Med World 91:203-205.
24. Kirsch I (1985) Response expectancy as a determinant of experience and behavior. Am Psychol 40:1189-1202.
25. Kirsch I (1999) How expectancies shape experience. Washington, DC: American Psychological Association.
26. Kirsch I, Weixel LJ (1988) Double-blind versus deceptive administration of a placebo. Behav Neurosci 102:319-323.
27. Kissel P, Barrucand D (1964) Placebos et effet placebo en medecine. Paris: Masson.
28. Laska E, Sunshine A (1973) Anticipation of analgesia: a placebo effect. Headache 13:1-11.
29. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M (2002) Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiat 159:122-129.
30. Levine JD, Gordon NC (1984) Influence of the method of drug administration on analgesic response. Nature 312:755-756.
31. Levine JD, Gordon NC, Fields HL (1978) The mechanisms of placebo analgesia. Lancet 2:654-657.
32. Levine JD, Gordon NC, Smith R, Fields HL (1981) Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain 10:379-389.
33. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339:1105-1111.
34. Lopiano L, Rizzone M, Bergamasco B, Tavella A, Torre E, Perozzo P, Valentini MC, Lanotte M (2001) Deep brain stimulation of the subthalamic nucleus: clinical effectiveness and safety. Neurology 56:52-54.
35. Lyerly SB, Ross S, Krugman AD, Clyde DJ (1964) Drugs and placebos: the effects of instructions upon performance and mood under amphetamine sulphate and chloral hydrate. J Abn Soc Psychol 68:321-327.
36. Mayberg HS, Silva AJ, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA (2002) The functional neuroanatomy of the placebo effect. Am J Psychiat 159:728-737.
37. Moerman DE (2002) Explanatory mechanisms for placebo effects: cultural influences and the meaning response. In: The science of the placebo: toward an interdisciplinary research agenda (Guess HA, Kleinman A, Kusek JW, Engel LW, eds), pp 77-107. London: BMJ Books.
38. Montgomery GH, Kirsch I (1997) Classical conditioning and the placebo effect. Pain 72:107-113.
39. 1D on basal and stimulated growth hormone secretion. J Clin Endocrinol Metab 80:1973-1977.
40. Petrovic P, Kalso E, Petersson KM, Ingvar M (2002) Placebo and opioid analgesia - imaging a shared neuronal network. Science 295:1737-1740.
41. Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F (2001) Response expectancies in placebo analgesia and their clinical relevance. Pain 93:77-84.
42. Pollo A, Torre E, Lopiano L, Rizzone M, Lanotte M, Cavanna A, Bergamasco B, Benedetti F (2002) Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. NeuroReport 13:1383-1386.
43. Pollo A, Vighetti S, Rainero I, Benedetti F (2003) Placebo analgesia and the heart. Pain 102:125-133.
44. Price DD (2000) Factors that determine the magnitude and presence of placebo analgesia. In: Proceedings of the 9th World Congress of Pain (Devor M, Rowbotham MC, Wiesenfeld-Hallin Z, eds), pp 1085-1095. Seattle, WA: IASP.
45. Price DD (2001) Assessing placebo effects without placebo groups: an untapped possibility? Pain 90:201-203.
46. Price DD (2002) Endogenous opioid and non-opioid pathways as mediators of placebo analgesia. In: The science of the placebo: toward an interdisciplinary research agenda (Guess HA, Kleinman A, Kusek JW, Engel LW, eds), pp 183-206. London: BMJ Books.
47. Price DD, Fields HL (1997) The contribution of desire and expectation to placebo analgesia: implications for new research strategies. In: The placebo effect: an interdisciplinary exploration (Harrington A, ed), pp 117-137. Cambridge, MA: Harvard UP.
48. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS (1999) An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83:147-156.
49. Rainero I, Valfrè W, Savi L, Gentile S, Pinessi L, Gianotti L, Arvat E, Ghigo E, Del Rizzo P, Calvelli P, Limone P (2001) Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine. J Endocrinol Invest 24:310-315.
50. 1D receptors in chronic tension-type headache. Headache 42:709-714.
51. Reiss S (1980) Pavlovian conditioning and human fear: an expectancy model. Behav Ther 11:380-396.
52. Rescorla RA (1988) Pavlovian conditioning: it's not what you think it is. Am Psychol 43:151-160.
53. Rizzone M, Lanotte M, Bergamasco B, Tavella A, Torre E, Faccani G, Melcarne A, Lopiano L (2001) Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: effects of variation in stimulation parameters. J Neurol Neurosurg Psychiat 71:215-219.
54. Schachter S, Singer JE (1962) Cognitive, social and physiological determinants of emotional states. Psychol Rev 69:379-399.
55. Siegel S (1985) Drug-anticipatory responses in animals. In: Placebo: theory, research, and mechanisms (White L, Tursky B, Schwartz GE, eds), pp 288-305. New York: Guilford.
56. Siegel S (2002) Explanatory mechanisms for placebo effects: Pavlovian conditioning. In: The science of the placebo: toward an interdisciplinary research agenda (Guess HA, Kleinman A, Kusek JW, Engel LW, eds), pp 133-157. London: BMJ Books.
57. Valverde I, Penalva A, Dieguez C (2000) Influence of different serotonin receptor subtypes on growth hormone secretion. Neuroendocrinology 7:145-153.
58. Voudouris NJ, Peck CL, Coleman G (1985) Conditioned placebo responses. J Perspect Soc Psychol 48:47-53.
59. Voudouris NJ, Peck CL, Coleman G (1989) Conditioned response models of placebo phenomena: further support. Pain 38:109-116.
60. Voudouris NJ, Peck CL, Coleman G (1990) The role of conditioning and expectancy in the placebo response. Pain 43:121-128.
61. Wickramasekera I (1980) A conditioned response model of the placebo effect: predictions from the model. Biofeed Self-Regul 5:5-18.
62. Wied GI (1953) Uber die Bedeutung der Suggesstion in der Therapie klimatkerischer Ausfallerscheinungen. Arztliche Wochenschrift 8:623-625.
63. Zappia M, Montesanti R, Colao R, Quattrone A (1994) Usefulness of movement time in the assessment of Parkinson's disease. J Neurol 241:543-550.